Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages

Patient selection for PI3K-targeted solid cancer treatment was based on the PIK3CA/PTEN mutational status. However, it is increasingly clear that this is not a good predictor of the response of breast cancer cells to the anti-proliferative effect of PI3K inhibitors, indicating that isoform(s) other...

Descripción completa

Detalles Bibliográficos
Autores principales: Goulielmaki, Evangelia, Bermudez-Brito, Miriam, Andreou, Margarita, Tzenaki, Niki, Tzardi, Maria, de Bree, Eelco, Tsentelierou, Eleftheria, Makrigiannakis, Antonis, Papakonstanti, Evangelia A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992183/
https://www.ncbi.nlm.nih.gov/pubmed/29880805
http://dx.doi.org/10.1038/s41419-018-0717-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992183/
https://www.ncbi.nlm.nih.gov/pubmed/29880805
http://dx.doi.org/10.1038/s41419-018-0717-4

Ejemplares similares